Aslan Fred 4
4 · Artiva Biotherapeutics, Inc. · Filed Nov 17, 2025
Insider Transaction Report
Form 4
Aslan Fred
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-11-15$3.25/sh−6,347$20,628→ 350,374 total - Sale
Common Stock
2025-11-17$3.38/sh−6,375$21,522→ 343,999 total
Footnotes (3)
- [F1]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F2]The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.
- [F3]The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.